Regeneron Pharmaceuticals, Inc., announced FDA approval of evinacumab-dgnb (Evkeeza) for children as young as 1 year of age with homozygous familial hypercholesterolemia (HoFH), expanding treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback